Anixa Biosciences partners with Curia on breast cancer vaccine formulation for Phase 2 trial
ANIX•Anixa Biosciences will work with Curia to develop a breast cancer vaccine formulation for an upcoming Phase 2 trial. In a 35-woman Phase 1 trial, 74% showed protocol-defined immune responses, and the vaccine met its primary endpoints.
1. Formulation development
Anixa Biosciences will collaborate with Curia on a formulation of its breast cancer vaccine for an upcoming Phase 2 trial. The work will target stability and manufacturing scalability to support future clinical studies and potential commercial production.
2. Phase 1 results
The vaccine, developed with Cleveland Clinic, met its primary endpoints in a 35-woman Phase 1 trial; 74% of participants showed protocol-defined immune responses.




